

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7930280

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
FIBROGEN, INC.	04/29/2023

RECEIVING PARTY DATA

Name:	WILMINGTON TRUST, NATIONAL ASSOCIATION
Street Address:	1100 NORTH MARKET STREET
City:	WILMINGTON
State/Country:	DELAWARE
Postal Code:	19890

PROPERTY NUMBERS Total: 91

Property Type	Number
Patent Number:	8124582
Patent Number:	7618940
Patent Number:	8202834
Patent Number:	8614204
Patent Number:	8629131
Patent Number:	8604012
Patent Number:	8609646
Patent Number:	8604013
Patent Number:	9920011
Patent Number:	10626090
Patent Number:	10894774
Patent Number:	10882827
Patent Number:	10927081
Patent Number:	7323475
Patent Number:	7629357
Patent Number:	7863292
Patent Number:	8017625
Patent Number:	8278325
Patent Number:	8916585
Patent Number:	8765956

PATENT

Property Type	Number
Patent Number:	9339527
Patent Number:	10092558
Patent Number:	10646482
Patent Number:	11229637
Patent Number:	8530404
Patent Number:	8703795
Patent Number:	9000006
Patent Number:	7928120
Patent Number:	8759373
Patent Number:	9174976
Patent Number:	9775902
Patent Number:	7696223
Patent Number:	7713986
Patent Number:	8269008
Patent Number:	8952160
Patent Number:	9387200
Patent Number:	8324405
Patent Number:	8217043
Patent Number:	8927591
Patent Number:	9149476
Patent Number:	8921389
Patent Number:	9271970
Patent Number:	9695170
Patent Number:	9409892
Patent Number:	9340511
Patent Number:	9708269
Patent Number:	9643928
Patent Number:	8883823
Patent Number:	9115085
Patent Number:	9371288
Patent Number:	9617218
Patent Number:	9918977
Patent Number:	10118897
Patent Number:	10272078
Patent Number:	10765672
Patent Number:	7405274
Patent Number:	7871617
Patent Number:	9034643

Property Type	Number
Patent Number:	8314059
Patent Number:	8865173
Patent Number:	8728468
Patent Number:	8088381
Patent Number:	8771692
Patent Number:	9587016
Patent Number:	9102721
Patent Number:	8802839
Patent Number:	9115356
Patent Number:	9480449
Patent Number:	10039515
Patent Number:	10555713
Patent Number:	9631013
Patent Number:	11299537
Patent Number:	8318703
Application Number:	17132743
Application Number:	17132491
Application Number:	17198013
Application Number:	17586620
Application Number:	17688717
Application Number:	17579581
Application Number:	17217953
Application Number:	17812923
Application Number:	18193463
Application Number:	18157728
Application Number:	18069918
Application Number:	18043117
Application Number:	18068977
Application Number:	63399483
Application Number:	63384203
Application Number:	63389607
Application Number:	63389610
Application Number:	17394602

CORRESPONDENCE DATA

Fax Number: (949)475-4754

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 949-451-3800

Email: skann@gibsondunn.com
Correspondent Name: STEPHANIE KANN
Address Line 1: 3161 MICHELSON DRIVE
Address Line 2: GIBSON, DUNN & CRUTCHER LLP
Address Line 4: IRVINE, CALIFORNIA 92612

ATTORNEY DOCKET NUMBER: 65485-00015

NAME OF SUBMITTER: STEPHANIE KANN

SIGNATURE: /stephanie kann/

DATE SIGNED: 05/01/2023

Total Attachments: 16

source=Fibrogen - Patent Security Agreement Executed#page1.tif
source=Fibrogen - Patent Security Agreement Executed#page2.tif
source=Fibrogen - Patent Security Agreement Executed#page3.tif
source=Fibrogen - Patent Security Agreement Executed#page4.tif
source=Fibrogen - Patent Security Agreement Executed#page5.tif
source=Fibrogen - Patent Security Agreement Executed#page6.tif
source=Fibrogen - Patent Security Agreement Executed#page7.tif
source=Fibrogen - Patent Security Agreement Executed#page8.tif
source=Fibrogen - Patent Security Agreement Executed#page9.tif
source=Fibrogen - Patent Security Agreement Executed#page10.tif
source=Fibrogen - Patent Security Agreement Executed#page11.tif
source=Fibrogen - Patent Security Agreement Executed#page12.tif
source=Fibrogen - Patent Security Agreement Executed#page13.tif
source=Fibrogen - Patent Security Agreement Executed#page14.tif
source=Fibrogen - Patent Security Agreement Executed#page15.tif
source=Fibrogen - Patent Security Agreement Executed#page16.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this “**Agreement**”), dated as of April 29, 2023 is entered into by and among, FibroGen, Inc., a Delaware corporation (the “**Grantor**”) and Wilmington Trust, National Association, as Administrative Agent (the “**Assignee**”) pursuant to (i) that certain Pledge and Security Agreement, dated as of April 29, 2023, among the Assignee, the Grantor and the other Grantors party thereto (as amended, restated, supplemented or otherwise modified from time to time, the “**Security Agreement**”), and (ii) that certain Financing Agreement, dated as of April 29, 2023 (as amended, restated, supplemented or otherwise modified from time to time, the “**Financing Agreement**”), between, among others, certain of the Grantor’s affiliates, the Assignee, and certain Lenders party thereto.

Capitalized terms not otherwise defined herein have the respective meanings ascribed to them in the Security Agreement or the Financing Agreement, as applicable.

WHEREAS, pursuant to the Security Agreement, the Grantor has granted in favor of the Assignee a security interest in certain Collateral, including the federally registered Patents set forth on Schedule A hereto as of the date hereof.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantor and the Assignee hereby agree as follows:

Grant of Security Interest

Subject to the terms and conditions of the Security Agreement, to evidence further the security interest granted by the Grantor to the Assignee pursuant to the Security Agreement, the Grantor hereby grants to the Assignee a security interest in all of the Grantor’s right, title and interest in, to and under the Patents, whether now owned or existing or at any time hereafter acquired or arising and wherever located, as collateral security for the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of the Grantor’s Secured Obligations. For the purposes of this Agreement, “Patents” means (i) all letters patent of the United States, all reissues and extensions thereof and all goodwill associated therewith, including, without limitation, any of the foregoing referred to on Schedule A hereto, (ii) all applications for letters patent of the United States, continuations and continuations-in-part thereof, including, without limitation, any of the foregoing referred to on Schedule A hereto, and (iii) all rights to obtain any reissues or extensions of the foregoing.

Schedule A hereto contains a true and accurate list of all of the Grantor’s federally registered United States registrations and applications for registration for the Patents existing as of the date hereof.

The security interest granted hereby is granted concurrently and in conjunction with the security interest granted to the Assignee under the Security Agreement. In the event that any of the provisions of this Agreement are in conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

Modifications

This Agreement or any provision hereof may not be changed, waived, or terminated except in accordance with the amendment provisions of the Financing Agreement. In connection with the foregoing, the Grantor authorizes the Assignee, upon notice to the Grantor, to modify this Agreement without obtaining the Grantor’s signature to such modification, to the extent that such modification constitutes an amendment of Schedule A hereto, to add any right, title or interest in any Patents owned or subsequently

acquired by the Grantor or to delete any reference to any right, title or interest in any Patents in which the Grantor no longer has or claims any right, title or interest. The Grantor additionally agrees to execute any additional agreement or amendment hereto as may be reasonably required by the Assignee from time to time, to subject any such owned or subsequently acquired right, title or interest in any Patent to the security interests and perfection created or contemplated hereby or by the Security Agreement.

Applicable Law

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.


Counterparts

This Agreement may be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by telecopy), and all of said counterparts taken together shall be deemed to constitute one and the same instrument.

IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.

GRANTOR:

FIBROGEN, INC.


By: 
Name: Juan Graham
Title: Vice President, Finance, and Chief
Financial Officer

Address of Grantor:
409 Illinois Street
San Francisco, CA 94158
Attention: Juan Graham and Michael Lowenstein
Email: jgraham@fibrogen.com;
mloenstein@fibrogen.com

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the date first above written.

ASSIGNEE:

**WILMINGTON TRUST, NATIONAL
ASSOCIATION,**
as Administrative Agent

By 
Name: **Joseph B. Feil**
Title: **Vice President**

Address of Assignee:

1100 North Market Street
Wilmington, DE 19890

SCHEDULE A
TO PATENT SECURITY AGREEMENT

Schedule A to PATENT SECURITY AGREEMENT

U.S. Registered Patents

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPLN. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
	FP060 2.1 US	Treatment of Diabetes	United States	Granted	10/729,704	12/04/2003	8124582	02/28/2012	12/04/2023	Fibro Gen, Inc.
	FP060 2.2 US	Fat Regulation	United States	Granted	10/729,167	12/04/2003	7618940	11/17/2009	12/04/2023	Fibro Gen, Inc.
	FP060 2.4 CON	Fat Regulation	United States	Granted	12/589,229	10/19/2009	8202834	06/19/2012	12/04/2023	Fibro Gen, Inc.
FP0606 WO2004/108121	FP060 6 US	Enhanced Erythropoiesis and Iron Metabolism	United States	Granted	10/861,590	06/03/2004	8614204	12/24/2013	06/03/2024	Fibro Gen, Inc.
	FP060 6.1 DIV	Enhanced Erythropoiesis and Iron Metabolism	United States	Granted	12/804,066	07/12/2010	8629131	01/14/2014	06/03/2024	Fibro Gen, Inc.
	FP060 6.2 DIV	Enhanced Erythropoiesis and Iron Metabolism	United States	Granted	12/804,033	07/12/2010	8604012	12/10/2013	06/03/2024	Fibro Gen, Inc.
	FP060 6.3 DIV	Enhanced Erythropoiesis and Iron Metabolism	United States	Granted	12/804,029	07/12/2010	8609646	12/17/2013	06/03/2024	Fibro Gen, Inc.
	FP060 6.4 CON	Enhanced Erythropoiesis and Iron Metabolism	United States	Granted	12/804,042	07/12/2010	8604013	12/10/2013	06/03/2024	Fibro Gen, Inc.
	FP060 6.5 DIV	Enhanced Erythropoiesis and Iron Metabolism	United States	Granted	14/084,443	11/19/2013	9920011	03/20/2018	06/03/2024	Fibro Gen, Inc.

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPLN. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
	FP060 6.7 CON	Enhanced Erythropoiesis and Iron Metabolism	United States	Granted	15/488,640	04/17/2017	10626090	04/21/2020	06/03/2024	Fibro Gen, Inc.
	FP060 6.9 CON	Enhanced Erythropoiesis and Iron Metabolism	United States	Granted	15/498,856	04/27/2017	10894774	01/19/2021	06/03/2024	Fibro Gen, Inc.
	FP060 6.10 CON	Enhanced Erythropoiesis and Iron Metabolism	United States	Granted	15/882,772	01/29/2018	10882827	01/05/2021	06/03/2024	Fibro Gen, Inc.
	FP060 6.11 CON	Enhanced Erythropoiesis and Iron Metabolism	United States	Granted	15/883,250	01/30/2018	10927081	02/23/2021	06/03/2024	Fibro Gen, Inc.
	FP060 6.12 CON	Enhanced Erythropoiesis and Iron Metabolism	United States	Allowed	17/132,743	12/23/2020				Fibro Gen, Inc.
	FP060 6.13 CON	Enhanced Erythropoiesis and Iron Metabolism	United States	Allowed	17/132,491	12/23/2020				Fibro Gen, Inc.
FP0613 WO2004/108681	FP061 3 US	Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Granted	10/861,082	06/04/2004	7323475	01/29/2008	06/04/2024	Fibro Gen, Inc.
	FP061 3.1 CON	Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Granted	11/442,727	05/26/2006	7629357	12/08/2009	06/04/2024	Fibro Gen, Inc.
	FP061 3.3 CON	Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Granted	11/624,949	01/19/2007	7863292	01/04/2011	06/04/2024	Fibro Gen, Inc.
	FP061 3.4 DIV	Novel Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Granted	12/015,275	01/16/2008	8017625	09/13/2011	06/04/2024	Fibro Gen, Inc.

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPLN. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
	FP061 3.5 CON	Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Granted	13/186,351	07/19/2011	8278325	10/02/2012	06/04/2024	Fibro Gen, Inc.
	FP061 3.6 CON	Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Granted	13/599,161	08/30/2012	8916585	12/23/2014	06/04/2024	Fibro Gen, Inc.
	FP061 3.7 CON	Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Granted	13/912,483	06/07/2013	8765956	07/01/2014	06/04/2024	Fibro Gen, Inc.
	FP061 3.8 CON	Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Granted	14/284,325	05/21/2014	9339527	05/17/2016	06/04/2024	Fibro Gen, Inc.
	FP061 3.9 CON	Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Granted	15/133,104	04/19/2016	10092558	10/09/2018	06/04/2024	Fibro Gen, Inc.
	FP061 3.10 CON	Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Granted	16/109,562	08/22/2018	10646482	05/12/2010	06/04/2024	Fibro Gen, Inc.
	FP061 3.11 CON	Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Granted	16/818,800	03/13/2020	11229637	01/25/2022	06/04/2024	Fibro Gen, Inc.
	FP061 9 US	Compounds and Methods for Treatment of Cancer	United States	Granted	11/455,199	06/15/2006	8530404	09/10/2013	06/15/2026	Fibro Gen, Inc.

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPLN. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
FP0623 WO2006/0 94292	FP062 3 US	Novel Thienopyridine Compounds and Methods of Use Thereof	United States	Granted	11/367,969	03/02/2006	8703795	04/22/2014	03/02/2026	Fibro Gen, Inc.
	FP062 3.1 DIV	Novel Thienopyridine Compounds and Methods of Use Thereof	United States	Granted	14/249,281	04/09/2014	9000006	04/07/2015	03/02/2026	Fibro Gen, Inc.
FP0627 WO2007/0 90068	FP062 7 US	Cyanoisoquinoline Compounds and Methods of Use Thereof	United States	Granted	11/627,906	01/26/2007	7928120	04/19/2011	01/26/2027	Fibro Gen, Inc.
	FP062 7.2 CON	Cyanoisoquinoline Compounds and Methods of Use Thereof	United States	Granted	13/430,568	03/26/2012	8759373	06/24/2014	01/26/2027	Fibro Gen, Inc.
	FP062 7.3 CON	Cyanoisoquinoline Compounds and Methods of Use Thereof	United States	Granted	14/289,573	05/28/2014	9174976	11/03/2015	01/26/2027	Fibro Gen, Inc.
FP0628 WO2007/0 97929	FP062 8.1 CON	Compounds and Methods for Treatment of Stroke	United States	Granted	13/180,262	07/11/2011	9775902	10/03/2017	02/08/2027	Fibro Gen, Inc.
FP0629 WO2007/1 15315	FP062 9 US	Pyrrolo- and Thiazolo-Pyridine Compounds as HIF Modulators	United States	Granted	11/696,549	04/04/2007	7696223	04/13/2010	04/04/2027	Fibro Gen, Inc.
FP0630 WO2007/1 46425	FP063 0 US	Compounds and Methods for Treatment of Chemotherapy-Induced Anemia	United States	Granted	11/455,200	06/15/2006	7713986	05/11/2010	06/15/2036	Fibro Gen, Inc.

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPLN. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
FP0641 WO2009/073669	FP0641 US	Isoxazolopyridine Derivatives for Use in the Treatment of HIF-Mediated Conditions	United States	Granted	12/734,895	08/16/2010	8269008	09/18/2012	12/02/2028	Fibro Gen, Inc.
FP0644 WO2009/089547	FP0644 US	Isothiazole-Pyridine Derivatives as Modulators of HIF (Hypoxia Inducible Factor) Activity	United States	Granted	12/811,821	09/14/2010	8952160	02/10/2015	01/12/2029	Fibro Gen, Inc.
	FP0644.1 DIV	Isothiazole-Pyridine Derivatives as Modulators of HIF (Hypoxia Inducible Factor) Activity	United States	Granted	14/609,216	01/29/2015	9387200	07/12/2016	01/12/2029	Fibro Gen, Inc.
FP0645 WO2009/100250	FP0645 US	Chromene Derivatives and Use Thereof as HIF Hydroxylase Activity Inhibitors	United States	Granted	12/866,023	09/14/2010	8324405	12/04/2012	02/05/2029	Fibro Gen, Inc.
FP0650 WO2010/022240	FP0650 US	Compounds and Methods for Their Use	United States	Granted	12/544,861	08/20/2009	8217043	07/10/2012	08/20/2029	Fibro Gen, Inc.
	FP0651 US	Thichromene Derivatives as HIF Hydroxylase Inhibitors	United States	Granted	13/128,620	08/22/2011	8927591	01/06/2015	11/11/2029	Fibro Gen, Inc.
FP0651 WO2010/056767	FP0651.1 CON	Thichromene Derivatives as HIF	United States	Granted	14/582,914	12/24/2014	9149476	10/06/2015	11/11/2029	Fibro Gen, Inc.

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPLN. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
		Hydroxylase Inhibitors								
FP0656 WO2012/106472	FP0656 US	Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase	United States	Granted	13/983,025	11/06/2013	8921389	12/30/2014	02/01/2032	Fibro Gen, Inc.
	FP0656.1 DIV	Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase	United States	Granted	14/581,592	12/23/2014	9271970	03/01/2016	02/01/2032	Fibro Gen, Inc.
	FP0656.2 CON	Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase	United States	Granted	15/043,286	02/12/2016	9695170	07/04/2017	02/01/2032	Fibro Gen, Inc.
FP0661 WO2013/134660	FP0661 US	4-Hydroxy-Isoquinoline Compounds as HIF Hydroxylase Inhibitors	United States	Granted	14/383,874	09/08/2014	9409892	08/09/2016	03/08/2033	Fibro Gen, Inc.
FP0663 WO2014/014834	FP0663 US	Process For Making Isoquinoline Compounds	United States	Granted	14/414,879	01/14/2015	9340511	05/17/2016	07/15/2033	Fibro Gen, Inc.
	FP0663.1 CON	Process For Making Isoquinoline Compounds	United States	Granted	15/073,251	03/17/2016	9708269	07/18/2017	07/15/2033	Fibro Gen, Inc.
FP0664 WO2014/116849	FP0664 US	Crystalline Forms of {[1-Cyano-5-(4-Chlorophenoxy)-4-Hydroxy-Isoquinoline-3-Carbonyl]-	United States	Granted	14/763,127	07/23/2015	9643928	05/09/2017	01/23/2034	Fibro Gen, Inc.

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPLN. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
		Amino}- Acetic Acid								
FP0666 WO2014/014835	FP066 6 US	Crystalline Forms of A Prolyl Hydroxylase Inhibitor	United States	Granted	13/942,370	07/15/2013	8883823	11/11/2014	07/15/2033	Fibro Gen, Inc.
	FP066 6.1 US	Crystalline Forms of A Prolyl Hydroxylase Inhibitor	United States	Granted	13/942,443	07/15/2013	9115085	08/25/2015	07/15/2033	Fibro Gen, Inc.
	FP066 6.2 CON	Crystalline Forms of A Prolyl Hydroxylase Inhibitor	United States	Granted	14/520,232	10/21/2014	9371288	06/21/2016	07/15/2033	Fibro Gen, Inc.
	FP066 6.3 CON	Crystalline Forms of A Prolyl Hydroxylase Inhibitor	United States	Granted	14/805,345	07/21/2015	9617218	04/11/2017	07/15/2033	Fibro Gen, Inc.
	FP066 6.4 CON	Crystalline Forms of A Prolyl Hydroxylase Inhibitor	United States	Granted	15/158,539	05/18/2016	9918977	03/20/2018	07/15/2033	Fibro Gen, Inc.
	FP066 6.5 CON	Crystalline Forms of A Prolyl Hydroxylase Inhibitor	United States	Granted	15/462,688	03/17/2017	10118897	11/06/2018	07/15/2033	Fibro Gen, Inc.
	FP066 6.6 CON	Crystalline Forms of A Prolyl Hydroxylase Inhibitor	United States	Granted	15/889,086	02/05/2018	10272078	04/30/2019	07/15/2033	Fibro Gen, Inc.
FP0667 WO2014/197660	FP066 7.1 CON	Pharmaceutical Formulations of A HIF Hydroxylase Inhibitor	United States	Granted	16/035,503	07/13/2018	10765672	09/08/2020	06/05/2034	Fibro Gen, Inc.
	FP066 7.3 CON	Pharmaceutical Formulations of A HIF Hydroxylase Inhibitor	United States	Published	17/198,013	03/10/2021				Fibro Gen, Inc.

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPLN. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
FP0814 WO2004/1 08764	FP081 4 US	Connective Tissue Growth Factor Antibodies	United States	Grante d	10/858, 186	06/01/2 004	74052 74	07/29/2 008	06/01/20 24	Fibro Gen, Inc.
	FP081 4.1 CON	Antibodies That Bind to a Portion of the VWC Domain of Connective Tissue Growth Factor	United States	Grante d	12/157, 262	06/09/2 008	78716 17	01/18/2 011	06/01/20 24	Fibro Gen, Inc.
	FP081 4.3 CON	Connective Tissue Growth Factor Antibodies	United States	Grante d	13/691, 356	11/30/2 012	90346 43	05/19/2 015	06/01/20 24	Fibro Gen, Inc.
FP0816 WO2005/0 77413	FP081 6.2 CON	Diabetic Nephropathy Therapies	United States	Grante d	12/802, 373	06/03/2 010	83140 59	11/20/2 012	02/11/20 25	Fibro Gen, Inc.
FP0819 WO2005/1 10479	FP081 9.2 CON	Treatments for Pancreatic Cancer Metastases	United States	Grante d	12/148, 922	04/23/2 008	88651 73	10/21/2 014	04/28/20 25	Fibro Gen, Inc.
	FP081 9.3 CON	Treatments for Cancer	United States	Grante d	13/611, 494	09/12/2 012	87284 68	05/20/2 014	04/28/20 25	Fibro Gen, Inc.
FP0834 WO2006/1 22047	FP083 4 US	Methods of Treatment of Cardiovascu lar Disease Using Anti- CTGF Agents	United States	Grante d	11/418, 624	05/05/2 006	80883 81	01/03/2 012	05/05/20 26	Fibro Gen, Inc.
FP0838 WO2011/0 02525	FP083 8 US	Methods for Treatment of Muscular Dystrophy	United States	Grante d	13/380, 489	03/14/2 012	87716 92	07/08/2 014	07/02/20 30	Fibro Gen, Inc.
FP0841 WO2012/0 61811	FP084 1.1 CON	Treatment Method for Lung	United States	Grante d	14/741, 747	06/17/2 015	95870 16	03/07/2 017	11/07/20 31	Fibro Gen, Inc.

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPLN. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
		Remodeling Diseases								
FP0842 WO2012/100262	FP084 2 US	Therapeutic Method	United States	Granted	13/980,806	01/17/2014	9102721	08/11/2015	01/23/2032	Fibro Gen, Inc.
FP0843 US2013/0178510	FP084 3 US	Connective Tissue Growth Factor Antisense Oligonucleotides	United States	Granted	13/546,799	07/11/2012	8802839	08/12/2014	07/11/2032	Fibro Gen, Inc.
	FP084 3.1 CON	Connective Tissue Growth Factor Antisense Oligonucleotides	United States	Granted	14/201,186	03/07/2014	9115356	08/25/2015	07/11/2032	Fibro Gen, Inc.
FP0847 WO2013/165590	FP084 7 US	Methods for Treating Idiopathic Pulmonary Fibrosis	United States	Granted	14/398,380	10/31/2014	9480449	11/01/2016	03/14/2033	Fibro Gen, Inc.
	FP084 7.1 CON	Methods for Treating Idiopathic Pulmonary Fibrosis	United States	Granted	15/263,767	09/13/2016	10039515	08/07/2018	03/14/2033	Fibro Gen, Inc.
	FP084 7.2 CON	Methods for Treating Idiopathic Pulmonary Fibrosis	United States	Granted	16/028,235	07/05/2018	10555713	02/11/2020	03/14/2033	Fibro Gen, Inc.
	FP084 7.4 CON	Methods for Treating Idiopathic Pulmonary Fibrosis	United States	Published	17/586,620	01/27/2022				Fibro Gen, Inc.
FP0848 US2015/0210760	FP084 8 US	Therapeutic Method for Pancreatic Cancer	United States	Granted	14/593,819	01/09/2015	9631013	04/25/2017	01/09/2035	Fibro Gen, Inc.
FP0854 WO2017/100193	FP085 4 US	Methods for Treatment of Motor Neuron Diseases	United States	Granted	16/060,301	06/07/2018	11299537	04/12/2022	12/06/2036	Fibro Gen, Inc.

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPLN. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
	FP085 4.1 CON	Methods for Treatment of Motor Neuron Diseases	United States	Published	17/688,717	03/07/2022				Fibro Gen, Inc.
FP0858 US2022/0144931	FP085 8.1 CON	Methods of Treatment of Muscular Dystrophies	United States	Published	17/579,581	01/19/2022				Fibro Gen, Inc.
FP0859 US2021/0301006	FP085 9 US	Methods of Treating Acute Respiratory Distress Syndrome	United States	Published	17/217,953	03/30/2021				Fibro Gen, Inc.
GAL4400	GAL4 400 P	Methods for Improving Kidney Function	United States	Granted	11/446,417	6/1/2006	8,318,703	11/27/2012		Fibro Gen, Inc.

U.S. Patent Applications

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPLN. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
FP0613 WO2004/108681	FP061 3.13 CON	Novel Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Pending	17/812,923	07/15/2022				Fibro Gen, Inc.
	FP061 3.14 CON	Novel Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof	United States	Pending	18/193,463	03/30/2023				Fibro Gen, Inc.

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPL N. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
FP0666 WO2014/ 014835	FP066 6.19 CON	Crystalline Forms of A Prolyl Hydroxylase Inhibitor	United States	Pendi ng	18/157 ,728	01/20/ 2023				Fibro Gen, Inc.
	FP066 6.20 CON	Crystalline Forms of A Prolyl Hydroxylase Inhibitor	United States	Pendi ng	18/069 ,918	12/21/ 2022				Fibro Gen, Inc.
FP0670 WO2022/ 047230	FP067 0 US	Compound s, Compositio ns and Methods for Histone Lysine Demethylase Inhibition	United States	Pendi ng	18/043 ,117	02/27/ 2023				Fibro Gen, Inc.
FP0814 WO2004/ 108764	FP081 4.8 CON	Connective Tissue Growth Factor Antibodies	United States	Pendi ng	18/068 ,977	12/20/ 2022				Fibro Gen, Inc.
FP0860	FP086 0 P	Anti-CCR8 Antibodies and Uses Thereof	United States	Pendi ng	63/399 ,483	08/19/ 2022				Fibro Gen, Inc.
FP0861	FP086 1 P	Therapeutic Method for Pancreatic Cancer	United States	Pendi ng	63/384 ,203	11/17/ 2022				Fibro Gen, Inc.
GAL4300	GAL4 300 P	Modified Anti- Galectin-9 Antibody and Uses Thereof	United States	Pendi ng	63/389 ,607	07/15/ 2022				Fibro Gen, Inc.
GAL4400	GAL4 400 P	Modified Anti- Galectin-9 Antibody and Uses Thereof	United States	Pendi ng	63/389 ,610	07/15/ 2022				Fibro Gen, Inc.
		Methods for Treating Anemia in Subjects Having Kidney	United States	Pendi ng	17/394 ,602	8/5/20 21				Fibro Gen, Inc.

FAMILY	DOCKET NO.	TITLE	TERRITORY / REGION	STATUS	APPL. N. NO.	FILING DATE	PATENT NO.	GRANT DATE	EXPIRATION DATE (w/o PTE or SPC)	RECORD OWNER
		Failure Using Inhibitors of Hypoxia-Inducible Factor (HIF) Hydroxylase								